Department of Pediatrics, Osaka University Graduate School of Medicine, Yamadaoka 2-2, Suita, 565-0871, Japan.
Department of Pediatrics, Suita Municipal Hospital, Suita, Japan.
Int J Hematol. 2011 Sep;94(3):285-290. doi: 10.1007/s12185-011-0916-6. Epub 2011 Aug 24.
Allogeneic hematopoietic stem cell transplantation is the only curative method for patients with familial hemophagocytic lymphohistiocytosis (FHL). We present a case of a 3-month-old girl with Munc13-4 mutation (FHL3), who underwent bone marrow transplantation (BMT) from her human leukocyte antigen-haploidentical mother following reduced intensity conditioning (RIC) with fludarabine, melphalan, and busulfan. Engraftment after BMT was generally uneventful, with only mild acute graft versus host disease. Munc13-4 protein was restored following BMT, and she is well and free of disease 14 months after BMT. These results suggest that BMT with RIC from a family haploidentical donor may sufficiently restore immune regulation in infants, while lessening treatment-related mortality and long-term sequelae.
异基因造血干细胞移植是家族性噬血细胞性淋巴组织细胞增多症(FHL)患者的唯一治愈方法。我们报告了 1 例 Munc13-4 突变(FHL3)的 3 月龄女婴,在经过氟达拉滨、马法兰和白消安的减低强度预处理(RIC)后,接受了来自其人类白细胞抗原单倍体供体的骨髓移植(BMT)。BMT 后造血恢复通常无并发症,仅有轻度急性移植物抗宿主病。BMT 后 Munc13-4 蛋白得到恢复,BMT 后 14 个月,她无病生存且状况良好。这些结果表明,来自家族单倍体供体的 RIC-BMT 可能足以恢复婴儿的免疫调节,同时降低治疗相关死亡率和长期后遗症。